PRINCETON, N.J., Jan. 12, 2006 (PRIMEZONE) -- The Bull Market Report (http://www.bullmarket.com), a long-term growth and income-generating focused online investment newsletter, announced today that it has provided subscribers with a look at some of the major happenings in the world of healthcare and biotech, involving such companies as Genentech (NYSE:DNA), Invitrogen (Nasdaq:IVGN), American Healthways (Nasdaq:AMHC), and Amgen (Nasdaq:AMGN), among others.
All paid and trial subscribers to The Bull Market Report can now receive immediate access to The Bull Market Report's exclusive daily reports. As a trial or paid subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/?refer=BMR79
In its report, The Bull Market Report wrote: "(Genentech) has introduced an element of uncertainty into results, but in our view, the uncertainty is mainly in short-term results -- namely in Avastin sales one quarter to the next. While this could change the complexion of 2006 sales (after all you never know how sales might work out from say Q406 to Q107), the peak sales outlook for Avastin isn't in question. This is a matter of pace and smoothness of sales."
In its coverage, The Bull Market Report looked at the following topics, among others:
-- What catalysts does Genentech have going for it in 2006?
-- With its stock up 14% since The Bull Market Report upgraded
its rating on Invitrogen, what type of appreciation can be
expected going forward?
-- Why does The Bull Market Report disagree with Goldman Sachs'
reasons for downgrading American Healthways?
-- Should investors be wary of Amgen's EPO-related litigation
with Swiss pharmaceutical giant Roche?
About The Bull Market Report
Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The Bull Market Report's Recommended List includes over 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. As a testament to the durability of its value-focused and fundamentally sound recommendations in both up and down markets, The Bull Market Report is one of the oldest continuously published investment newsletters online. Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/?refer=BMR79
Subscribers also receive access to The Bull Market Report's special bonus reports, "Search Sector Outlook," "Biotech Sector Outlook," and "Understanding the Value of Insider Trading Data."
Note: This release was published by Indie Research, LLC (CRD #131926). Indie Research, LLC and the Bull Market editorial staff are not registered investment advisors, broker/dealers, or research analysts/organizations.